CN115697357A - T细胞细胞毒性的调节和相关治疗 - Google Patents

T细胞细胞毒性的调节和相关治疗 Download PDF

Info

Publication number
CN115697357A
CN115697357A CN202180041305.5A CN202180041305A CN115697357A CN 115697357 A CN115697357 A CN 115697357A CN 202180041305 A CN202180041305 A CN 202180041305A CN 115697357 A CN115697357 A CN 115697357A
Authority
CN
China
Prior art keywords
cells
cell
engineered
genes
sirpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041305.5A
Other languages
English (en)
Chinese (zh)
Inventor
塞尔吉奥·克萨达
卡尔·佩格斯
查尔斯·斯旺顿
伊赫桑·霍拉尼
詹姆斯·雷丁
费莉佩·加尔韦斯-坎西诺
德斯波伊纳·卡拉詹尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of CN115697357A publication Critical patent/CN115697357A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
CN202180041305.5A 2020-04-17 2021-04-16 T细胞细胞毒性的调节和相关治疗 Pending CN115697357A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2005599.2 2020-04-17
GBGB2005599.2A GB202005599D0 (en) 2020-04-17 2020-04-17 Modulation of t cell cytotoxicity and related therapy
PCT/EP2021/059989 WO2021209627A1 (en) 2020-04-17 2021-04-16 Modulation of t cell cytotoxicity and related therapy

Publications (1)

Publication Number Publication Date
CN115697357A true CN115697357A (zh) 2023-02-03

Family

ID=70859980

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041305.5A Pending CN115697357A (zh) 2020-04-17 2021-04-16 T细胞细胞毒性的调节和相关治疗

Country Status (12)

Country Link
US (1) US20230158073A1 (https=)
EP (1) EP4135725A1 (https=)
JP (1) JP2023521436A (https=)
KR (1) KR20230004643A (https=)
CN (1) CN115697357A (https=)
AU (1) AU2021255917A1 (https=)
BR (1) BR112022020819A2 (https=)
CA (1) CA3175622A1 (https=)
GB (1) GB202005599D0 (https=)
IL (1) IL297309A (https=)
MX (1) MX2022012924A (https=)
WO (1) WO2021209627A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022061115A1 (en) * 2020-09-18 2022-03-24 Vor Biopharma Inc. Compositions and methods for cd7 modification
CN115058504B (zh) * 2022-07-14 2025-07-04 广州医科大学 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用
WO2025063257A1 (ja) * 2023-09-22 2025-03-27 国立大学法人大阪大学 制御性ｔ細胞を製造する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
CN103946952A (zh) 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
KR20170068504A (ko) * 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
KR102546839B1 (ko) * 2016-08-03 2023-06-23 워싱턴 유니버시티 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
WO2018183921A1 (en) * 2017-04-01 2018-10-04 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EP3622092A4 (en) * 2017-05-11 2021-06-23 The Broad Institute, Inc. METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
CN110944652A (zh) * 2017-06-12 2020-03-31 爱莫里大学 T细胞抗原靶向的嵌合抗原受体(car)以及在细胞疗法中的用途

Also Published As

Publication number Publication date
US20230158073A1 (en) 2023-05-25
BR112022020819A2 (pt) 2022-11-29
MX2022012924A (es) 2023-04-03
KR20230004643A (ko) 2023-01-06
WO2021209627A1 (en) 2021-10-21
AU2021255917A1 (en) 2022-11-17
CA3175622A1 (en) 2021-10-21
IL297309A (en) 2022-12-01
EP4135725A1 (en) 2023-02-22
JP2023521436A (ja) 2023-05-24
GB202005599D0 (en) 2020-06-03

Similar Documents

Publication Publication Date Title
JP6815992B2 (ja) キメラ抗原受容体療法に対する治療応答性を予測するバイオマーカーおよびその使用
ES2971659T3 (es) Procedimiento para la producción de una composición de células T
EP4211228B1 (en) T cell phenotypes associated with response to adoptive cell therapy
US20190192565A1 (en) Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
AU2018342245A1 (en) Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation
CN115697357A (zh) T细胞细胞毒性的调节和相关治疗
US20240091259A1 (en) Generation of anti-tumor t cells
CN110691792A (zh) 细胞疗法的表观遗传学分析及相关方法
WO2022272245A2 (en) Unique cancer associated fibroblast subsets predict response to immunotherapy
US20220033464A1 (en) Methods and compositons for modulations of immune response
US20250257388A2 (en) Pre-effector car-t cell gene signatures
CA3220820A1 (en) Methods of treating cancer with cd-40 agonists
Verma et al. Early expression of CD94 and loss of CD96 on CD8+ T cells after allogeneic stem cell tranplantation is predictive of subsequent relapse and survival
US20250236915A1 (en) Cd4+ t cell markers, compositions, and methods for cancer
Guillen Understanding How T Cell Receptor Recognition and Signaling Impacts CD8+ T Cell Functional Programming
Gray et al. Agnieszka Goral1, Malgorzata Firczuk1, Klaudyna Fidyt1, Marta Sledz1, Francesca Simoncello2, Karolina Siudakowska1, Giulia Pagano3, Etienne Moussay3, Jeroˆme Paggetti3, Patrycja Nowakowska1, Stefania Gobessi4, Joanna Barankiewicz5, Aleksander Salomon-Perzynski5, Federica Benvenuti2, Dimitar G. Efremov4, Przemyslaw Juszczynski5, Ewa Lech-Maranda5 and Angelika Muchowicz1
HK40112725A (zh) 新型个体化新抗原疫苗和标志物
Greenplate A Comprehensive Framework for Systems Immune Monitoring in Patients with Cancer
Chaudhuri et al. Mediator Complex Subunit 1 Promotes Differentiation and Function of a Tumor-Specific T Regulatory Cell Population

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination